Group 1 - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. submitted its Hong Kong IPO application on August 21, 2025, which will expire on February 21, 2026, with Guotai Junan Securities (Hong Kong) as the sole sponsor [1] - The company focuses on the development of innovative drugs, specifically targeting allergic and autoimmune diseases, and has established a comprehensive pipeline of biopharmaceutical products across various medical fields [2] - Tianchen Biopharmaceuticals aims to leverage its expertise in innovative drug development, two self-developed technology platforms (high-affinity antibody discovery platform and bispecific antibody development platform), and strong R&D capabilities to create innovative drugs for allergic and autoimmune diseases [2]
新股消息 | 天辰生物医药港股IPO招股书失效
Zhi Tong Cai Jing·2026-02-24 01:13